论文部分内容阅读
目的了解新生儿感染大肠杆菌及耐药情况,为临床治疗及新生儿感染的控制提供依据。方法对本院2007年4月-2008年5月临床检出菌,用法国生物梅里埃系统VITEK2-COMPACT鉴定及药敏分析,并用双纸片法对新生儿科分离的大肠杆菌进行超广谱β-内酰胺酶(extend-spectrum β-lactamases,ESBLs)检测,同时对产ESBLs及非产ESBLs菌株进行耐药性分析。结果新生儿病房总共检出大肠杆菌113株,其中检出ESBLs阳性菌株66株,产酶率为58.41%。在12种抗生素中,耐药率最低的是亚胺培南。将47株ESBLs阴性的大肠杆菌平均耐药率与66株ESBLs阳性的大肠杆菌的平均耐药率相比较差异有显著性。结论新生儿病房等免疫力低下的患者是大肠杆菌的易感人群,且以呼吸道感染为主。治疗感染产ESBLs大肠杆菌的有效药物为抗生素与酶抑制的复方制剂和亚胺培南。
Objective To understand the neonatal infection of Escherichia coli and drug resistance, provide the basis for clinical treatment and neonatal infection control. Methods The clinical isolates from April 2007 to May 2008 in our hospital were identified by VITEK2-COMPACT and susceptibility analysis by French bioMérieux system. Escherichia coli isolated from neonates were treated with double disc method for extended spectrum β - extend-spectrum β-lactamases (ESBLs) were detected in ESBLs-producing ESBLs-producing strains and non-drug resistance analysis. Results A total of 113 strains of Escherichia coli were detected in the newborn ward, of which 66 strains were positive for ESBLs. The enzyme production rate was 58.41%. Of the 12 antibiotics, imipenem is the least resistant. The average drug resistance rate of 47 ESBLs-negative Escherichia coli strains was significantly different from that of 66 ESBLs-positive Escherichia coli strains. Conclusion Neonatal wards and other immunocompromised patients are susceptible to Escherichia coli, and mainly respiratory infections. Effective drugs for the treatment of ESBLs-producing Escherichia coli are antibiotics and enzyme inhibitors and imipenem.